Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen's disease): A randomized, double-blind, placebo-controlled trial
- 30 June 2006
- journal article
- research article
- Published by Elsevier BV in Journal of the American Academy of Dermatology
- Vol. 54 (6), 1025-1032
- https://doi.org/10.1016/j.jaad.2006.01.055
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histologyJournal of the American Academy of Dermatology, 2004
- Efficacy of imiquimod for the expression of Bcl-2, Ki67, p53 and basal cell carcinoma apoptosisBritish Journal of Dermatology, 2004
- Tumor-Selective Induction of Apoptosis and the Small-Molecule Immune Response Modifier ImiquimodJNCI Journal of the National Cancer Institute, 2003
- The Effects of 5% Imiquimod Cream on High-Grade Vulval Intraepithelial NeoplasiaGynecologic Oncology, 2002
- Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathwayNature Immunology, 2002
- Imiquimod 5% cream in the treatment of Bowen's diseaseJournal of the American Academy of Dermatology, 2001
- Guidelines for management of Bowen's diseaseBritish Journal of Dermatology, 1999
- Bowen's disease (squamous cell carcinoma in situ) in Kauai, Hawaii: A population-based incidence reportJournal of the American Academy of Dermatology, 1994
- Cryotherapy for skin cancer: results over a 5-year period using liquid nitrogen spray cryosurgeryBritish Journal of Dermatology, 1988
- THE PRECURSORS OF CUTANEOUS SQUAMOUS CELL CARCINOMAInternational Journal of Dermatology, 1979